Medeon's strengths lie in its team, which brings expertise, experience and insight into every step of the medical device lifecycle. We have successful entrepreneurs and investors with exemplary records in identifying key unmet, overlooked and emerging clinical needs and building them into successful projects. Our research and design experts develop devices that have not only passed the most rigorous regulatory standards, but are also readily adopted by healthcare professionals around the globe.
Chairman and CEO
For over 30 years Dr. Jang has brought novel devices to patients around the world, both as an investor and an entrepreneur. He spent 13 years as General Partner with The Vertical Group, and led prominent medtech companies including Kyphon (acquired by Medtronic), Integrated Vascular Systems (acquired by Abbott), Ensure Medical (acquired by J&J), and Embol-X (acquired by Edwards Lifesciences). Before that, Dr. Jang was Vice president of R&D at Boston Scientific and Vice president for R&D at Cardiovascular Imaging Systems. Dr. Jang currently sits on the boards of Tricorntech.
In 2012, Dr. Jang founded Medeon to bring revolutionary solutions to the medtech sector. He has also become a key mentor for young medtech talent; for instance, he co-founded the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings the best young leaders from Taiwan's medical field to Stanford for multi-disciplinary trainings including biodesign and entrepreneurship.
Dr. Jang received his B.S. in Materials Science from National Tsing-Hua University and completed his Ph.D. in Materials Science at the University of Utah.
Vice President & Chief Financial Officer
Ms. Huang is Medeon’s head of finance, accounting, human resources, IT, and administration. In this role she leverages her experience with major firms such as PricewaterhouseCoopers. After migrating to the biotech industry, she was responsible for finance and administration in XinChen Investment Corporation. Ms. Huang has also held analyst roles in Yuanta Securities Investment Consulting and Nokia Taiwan.
Ms. Huang received her bachelor's degree in Accounting from Soochow University in Taiwan.
Executive Vice President
Dr. Chen serves as the Executive Vice President at Medeon. She is a Biochemist by training, and brings over 15 years of venture and industry experience to lead Medeon in Business development and Product development. Prior to joining Medeon, Dr. Chen was Vice President at iD Innovation and Portfolio Manager with the Hotung Venture Capital Group. Her expertise spans a broad spectrum of fields from ICT, automobile, biopharmaceutical and medtech to digital health and distribution, across both the US and Greater China.
Dr. Chen earned her B.S. degree in Chemistry from the National Taiwan University, and a DPhil degree in Biochemistry from the University of Oxford.
VP of Implantable Products
Dr. Venkateswara-Rao serves as COO of US subsidiary & VP of Implantable Products, based in the Sunnyvale, California office. Dr. Rao brings 25 years of global commercialization experience with medical technologies to treat cardio-, neuro-, peripheral-vascular, and autonomic diseases. His leadership spans research and development, regulatory, quality, clinical affairs and manufacturing operations.
He began his career at the University of California & Lawrence Berkeley National Laboratory, followed by Guidant, J&J-Cordis, Nellix, Relisys (India) and QTVascular (Singapore). He was co-founder and CEO of Northwind Medical prior to joining Medeon. He is the inventor/author of more than 60 patents and scientific publications.
Dr. Rao holds a Ph.D. in Materials Science and Engineering from the University of California at Berkeley, an M.S. from Purdue University, and a B.S. from the Indian Institute of Technology at Madras, India.
VP of Cardiothoracic Surgery Products
Mr. Palermo leads Medeon's Aquedeon project. He is a veteran of the medical device industry with over 30 years of experience and a proven track record in positioning start-up companies for commercialization and successful acquisition. His skills encompass venture fundraising, business development, strategic planning, product development and executive management of companies spanning several market segments with diverse regulatory requirements.
Mr. Palermo has served as chief operating officer of Dextera Surgical, acting CEO of UlceRx Medical, Inc, and medical device consultant for Adjuvant Medical. He was also President and CEO of ReVascular Therapeutics (Acquired by Boston Scientific, 2011), Vice President of Operations and Engineering for Ensure Medical (Acquired by Cordis, J&J, 2006), and Director of Research and Development at Integrated Vascular Systems (Acquired by Abbott Vascular, 2003).
Mr. Palermo received his B.S. in Technical Management from New Hampshire College.
VP of Commercial Operations
Mr. Timothy D. Buckley leads Medeon’s commercial operations strategy.
Mr. Buckley has over 20 years of experience with global market entry, sales, and marketing strategy, focusing on both early stage market development, launch strategy, and global commercialization. He has a succeeded across a broad range of medical markets – including devices and implants for ophthalmology, ENT, laparoscopic, and cardiovascular therapies.
Prior to joining Medeon, Mr. Buckley was co-founder and CEO of Ocunetics, Inc., (acquired by Iridex). He led U.S. and global sales as Vice President of Global Marketing and Business Development after joined Iridex. Prior to that, he worked at Transcend Medical (acquired by Alcon) and at Carl Zeiss Meditec where he led marketing for its North American ophthalmic surgery division.
Mr. Buckley holds a B.S. in Mechanical Engineering from the University of California at Berkeley and an MBA from Santa Clara University.
VP of Interventional Products
Dr. Weng serves as Medeon’s Vice President of Interventional Products. He leads Cross-Seal project, which was successfully licensed to Terumo in March, 2018. Dr. Weng is responsible for R&D and co-development service assigned by client.
Before joining Medeon, Dr. Weng was a senior scientist and principle investigator at the Industrial Technology Research Institute (ITRI), where he led advanced technology and product development projects for commercialization. Dr. Weng brings over 20 years of experience in cardiovascular, orthopedic, and liver disease treatments as well as cell therapy. He is the inventor/author of more than 30 patents and scientific publications including in high impact factor journals.
Dr. Weng received his M.S. in Biochemical Sciences at the National Taiwan University, and completed his Ph.D. in Materials Sciences and Engineering at the National Tsing-Hua University. He was also a visiting scientist at the Massachusetts Institute of Technology (MIT).
VP of Regulatory, Quality & Clinical Affairs
Ms. Chang is the head of Regulatory, Quality and Clinical Affairs. She brings over 20 years’ experiences in medical device field to lead Medeon in strategy planning and execution related to regulatory pathway, quality control and clinical execution for each project.
Prior to joining Medeon, Ms. Chang was QA Manager at Health & Life Corporation and Regulatory Manager at Lite-On IT’s healthcare division. She also worked as senior lead auditor for TUV Rheinland. Ms. Chang received her B.S. in Biomedical Engineering from Chung Yuan Christian University.
VP of Legal & IP
Mr. Wang serves as the Vice President of Legal and IP at Medeon. With over 15 years of experience in LCD and semiconductor industry, he has shown his great leadership in handling general legal affairs, intellectual property (such as transaction, disputes, and protection), anti-trust investigation and litigation, corporate governance and legal compliance. Prior to joining Medeon, he leaded Legal and IP department at Etron Technology as Associate Vice President. He also worked as director of Legal department at Chunghwa Picture Tubes.
Mr. Wang received his LL.B. in Law from Fu-Jen Catholic University in Taiwan, and completed his LL.M. in Law at University of Minnesota-Twin Cities.
VP & General Manager of Asia Market
Dr. Tsai serves as the Vice President and General Manager of Asia Market at Medeon Biodesign. With expertise in innovative product development, new market access, and business strategy, Dr. Tsai brings over 20 years of medtech industry experience to Medeon to lead the business development of Asia markets, including China.
Prior to joining Medeon, Dr. Tsai was one of the founding team members at Bionime, an emerging company commercializing glucose monitoring solutions, and served various management roles in R&D, QA, and sales and marketing for the China market. While he was the Biodesign visiting scholar at Stanford University, he continued to found iXensor, an innovative company in developing point-of-care diagnostic solutions, and served as the Chairman and CEO responsible for general management, operations, and funding raising.
Dr. Tsai holds a Ph.D. degree in Chemistry from National Chung-Hsing University, and was a visiting scholar of the Biodesign Program at Stanford University.
Spokesperson and Deputy Chief Financial Officer
Dr. Jenny Chen, Spokesperson and Deputy Chief Financial Officer Dr. Chen serves as the spokesperson and deputy chief financial officer of Medeon Biodesign. With nearly 20 years of investment and business development experience, Dr. Chen contributes her expertise in strategic investment and due diligence, business development, and financial planning to the Medeon group. Prior to joining Medeon, Dr. Chen was the investment manager of the Taiwan Global Biofund, a leading global biotech venture capital firm based in Taipei, and participated in the initial founding process of Medeon Biodesign. Dr. Chen also held various leadership roles in business development and project management across the healthcare industry, including BioDiscovery, a bioinformatics product company in California, and Industrial Technology Research Institute (ITRI) of Taiwan.
Dr. Chen holds a Ph.D. degree in Microbiology from UC Davis, and an MBA degree in Finance from Rady School of Management, UC San Diego.
Chairman and CEOFor 30+ years Dr. Jang has brought novel devices to patients around the world, both as an investor and an entrepreneur. He spent 13 years as general partner with The Vertical Group, and led prominent medtech companies including Kyphon (acquired by Medtronic), Integrated Vascular Systems (acquired by Abbott), Ensure Medical (acquired by J&J), and Embol-X (acquired by Edwards Lifesciences). Before that, Dr. Jang was vice-president of R&D at Boston Scientific and vice-president for R&D at Cardiovascular Imaging Systems. Dr. Jang currently sits on the boards of Tricorntech. In 2012, Dr. Jang founded Medeon to bring revolutionary solutions to the minimally invasive medtech sector. He has also become a key mentor for young medtech talent; for instance, he co-founded the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings the best young leaders from Taiwan’s medical field to Stanford for multi-disciplinary trainings including biodesign and entrepreneurship.
Board DirectorDr. Hong-Jen Chang is currently Chairman and CEO of YFY Biotech Management Company and leads its highly successful Taiwan Global BioFund (TGB), working closely with early-stage founders in the healthcare space. Before joining YFY Group, Dr. Chang enjoyed a distinguished career of public service in healthcare, including serving as deputy minister of health, president & CEO of the Bureau of National Health Insurance, and director general of the Center of Disease Control. This combination of expertise in health insurance, disease control, biopharmaceutical industry, health information systems and venture investing makes Dr. Chang one of the most unique and well-respected leaders in the healthcare space. Dr. Chang received his Master of Science in Public Health from National Taiwan University, and Master of Health Policy and Management from Harvard School of Public Health.
Board DirectorA self-proclaimed “physician for life”, Dr. Chih-Hsiung Wu has overseen the establishment of entire hospital systems. Currently serving as CEO of Hsing Tian Kong Foundation Medical Mission and as the Superintendent of En Chu Kong Hospital, Dr. Wu is also Chair professor of Taipei Medical University and the Executive Director of Taiwan Hospital Association. He has also held numerous roles in clinical medicine, medical education and hospital management. After graduating from Taipei Medical University and completing his surgical training at the Chang Gung Memorial Hospital, Dr. Wu went on to receive his Ph.D. from Dokkyo Medical University in Japan.
Board DirectorDr. Fang is a well-respected surgeon in Taiwan and an active leader in promoting better training programs for residents. In addition to being a Professor of Surgery at the China Medical University (CMU), Dr. Fang is also Associate Dean of Department of Surgery of the CMU Hospital, and takes an active interest in emerging medical technologies. For instance, he has served as Director of CMU Hospital’s 3D Printing Medical Research Center. Dr. Fang completed his undergraduate studies at the Kaohsiung Medical College’s School of Medicine (1994), and received his Ph.D. from the National Taiwan University School of Medicine (2011, Surgical Science Division).
Independent Board DirectorDr. Chih-Hang Yang has mentored many of Taiwan's promising biotech and medtech founders. He played an instrumental role in the creation of the Stanford-Taiwan Biomedical Fellowship Program (STB), which brings young medical leaders from Taiwan to Stanford University for multi-disciplinary trainings in biodesign and medtech entrepreneurship. Dr. Yang’s career has spanned the academic, entrepreneurial and governmental. He was Chairman of Department of Computer Science at Tamkang University and later the dean of academic affairs and vice president of National Kaohsiung First University of Science and Technology. He also served as director general of the Department of International Programs of the National Science Council (now Ministry of Science and Technology), and was later appointed as the director of Science and Technology Division, TECO in San Francisco (effectively Taiwan’s representative on science and technology in Silicon Valley). Dr. Yang received his B.S. degree in Electronic Engineering from Tatung University, and earned both his Master and Ph.D. degree in Electronics and Computer Science at Southampton University in the UK. He also sits on the board of the Taiwan Cultural and Creativity Development Foundation.
Independent Board DirectorA licensed CPA in the United States, Taiwan and China, Dr. Chia-Ying Ma is currently Dean of Office of Research Development and Professor in the Department of Accounting in Soochow University, Taiwan. He is a sought-after consultant for many government committees including the Public Service Pension Fund, the Directorate-General of Budget for Accounting and Statistics, and the National Palace Museum. He received his B.S. degree in Accounting from National ChengChi University, Master's Degree in Accounting from Utah State University, and a Ph.D. Degree in Business and Economics from Lehigh University.
Independent Board DirectorDr. Shen is a noted venture investor with over 20 years of experience in a wide spectrum of healthcare sectors and has held executive positions in portfolio companies in the United States and Greater China. Dr. Shen is currently General Partner and Head of Life Science Investments of Taiwania Capital, the Taiwan government's national investment firm. Dr. Shen was previously President of Allgenesis Biotherapeutics, President of XinChen Ventures, and Managing Director of Cheng Xin Venture Group. Dr. Shen has been a key leader in nurturing early-stage startups and incubating academic projects into biopharmaceutical and medical device businesses. He received his B.S. degree in Chemical Engineering from the National Tsing-Hua University, and his Ph.D. in Chemical Engineering from the University of Wisconsin, Madison.